JP2006526031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526031A5 JP2006526031A5 JP2006519178A JP2006519178A JP2006526031A5 JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5 JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003148073 | 2003-05-26 | ||
| PCT/JP2004/007562 WO2004103369A1 (en) | 2003-05-26 | 2004-05-26 | Pharmaceutical composition containing histone deacetylase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526031A JP2006526031A (ja) | 2006-11-16 |
| JP2006526031A5 true JP2006526031A5 (enExample) | 2006-12-28 |
Family
ID=33475383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006519178A Pending JP2006526031A (ja) | 2003-05-26 | 2004-05-26 | ヒストンデアセチラーゼ阻害物質を含む医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20070098816A1 (enExample) |
| EP (1) | EP1626719A1 (enExample) |
| JP (1) | JP2006526031A (enExample) |
| KR (1) | KR100938712B1 (enExample) |
| CN (2) | CN101322707A (enExample) |
| AR (1) | AR045318A1 (enExample) |
| AU (1) | AU2004241873C1 (enExample) |
| BR (1) | BRPI0410959A (enExample) |
| CA (4) | CA2634709A1 (enExample) |
| CL (1) | CL2004001278A1 (enExample) |
| CO (1) | CO5660262A2 (enExample) |
| CR (1) | CR8163A (enExample) |
| CU (1) | CU23490B7 (enExample) |
| EC (1) | ECSP056253A (enExample) |
| IL (1) | IL171941A0 (enExample) |
| ME (1) | MEP32308A (enExample) |
| MX (1) | MXPA05012345A (enExample) |
| NO (1) | NO20055417L (enExample) |
| NZ (1) | NZ543591A (enExample) |
| PE (1) | PE20050206A1 (enExample) |
| RS (1) | RS20050884A (enExample) |
| RU (1) | RU2322971C2 (enExample) |
| TW (1) | TW200505424A (enExample) |
| UA (1) | UA81499C2 (enExample) |
| UY (1) | UY28330A1 (enExample) |
| WO (1) | WO2004103369A1 (enExample) |
| ZA (1) | ZA200509515B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2006520796A (ja) | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼインヒビター |
| EP2263694B1 (en) | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin |
| US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
| EP1712552A1 (en) * | 2005-04-11 | 2006-10-18 | INDENA S.p.A. | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
| WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006223086A1 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR20080032188A (ko) | 2005-07-14 | 2008-04-14 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| US8222423B2 (en) | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| CN103739515B (zh) | 2006-02-14 | 2015-11-25 | 哈佛大学的校长及成员们 | 组蛋白去乙酰化酶抑制剂 |
| CA2654540C (en) | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| CA2674084C (en) * | 2006-12-26 | 2013-05-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| WO2009079375A1 (en) * | 2007-12-14 | 2009-06-25 | Georgetown University | Histone deacetylase inhibitors |
| CA2731730C (en) | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
| GB2462893B (en) * | 2008-08-29 | 2010-10-13 | Bayer Schering Pharma Ag | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B |
| PE20141062A1 (es) * | 2008-08-29 | 2014-09-19 | Bayer Ip Gmbh | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) |
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| US20120034302A1 (en) * | 2009-02-11 | 2012-02-09 | Liangping Yu | Particulate composition and the method of making the same |
| JP2012525371A (ja) * | 2009-05-01 | 2012-10-22 | オンコザイム・ファーマ・インコーポレイテッド | 癌を治療するためのペンタミジンの組み合わせ |
| WO2010144371A1 (en) * | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| CN102573832B (zh) * | 2009-08-25 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗 |
| EP2569313A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| RU2609833C2 (ru) | 2011-09-13 | 2017-02-06 | Фармасайкликс Элэлси | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение |
| EP3878851A1 (en) | 2011-09-30 | 2021-09-15 | Vertex Pharmaceuticals Incorporated | Process for making compounds useful as inhibitors of atr kinase |
| RU2018108589A (ru) | 2011-09-30 | 2019-02-25 | Вертекс Фармасьютикалз Инкорпорейтед | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr |
| WO2013085902A1 (en) * | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| PT2833973T (pt) | 2012-04-05 | 2017-12-21 | Vertex Pharma | Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos |
| WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| EP2968282B1 (en) | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| WO2014141129A2 (en) * | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
| WO2015127227A1 (en) * | 2014-02-21 | 2015-08-27 | Cleveland Biolabs, Inc. | Uses of flagellin for improved chemotherapy |
| ES2751464T3 (es) | 2014-09-17 | 2020-03-31 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa |
| EP3355926B1 (en) | 2015-09-30 | 2025-12-24 | Vertex Pharmaceuticals Inc. | Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
| WO2025041160A1 (en) * | 2023-08-19 | 2025-02-27 | Birla Institute Of Technology And Science (Bits), Pilani | Bifunctional conjugate molecules for cancer treatment and process of making the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US6794392B1 (en) * | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
| JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| US5753637A (en) * | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| OA11659A (en) * | 1998-09-25 | 2004-12-08 | Warner Lambert Co | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. |
| AU4144400A (en) * | 1999-04-27 | 2000-11-10 | Mitsubishi Pharma Corporation | Preventives/remedies for liver diseases |
| JP2003513912A (ja) * | 1999-11-10 | 2003-04-15 | ワーナー−ランバート・カンパニー | 組合せ化学療法 |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| JP2003137866A (ja) * | 2001-11-01 | 2003-05-14 | Sankyo Co Ltd | フェニレンジアミン誘導体 |
-
2004
- 2004-05-25 PE PE2004000533A patent/PE20050206A1/es not_active Application Discontinuation
- 2004-05-26 ME MEP-323/08A patent/MEP32308A/xx unknown
- 2004-05-26 MX MXPA05012345A patent/MXPA05012345A/es active IP Right Grant
- 2004-05-26 EP EP04734923A patent/EP1626719A1/en not_active Withdrawn
- 2004-05-26 BR BRPI0410959-7A patent/BRPI0410959A/pt not_active IP Right Cessation
- 2004-05-26 RU RU2005140570/15A patent/RU2322971C2/ru active IP Right Revival
- 2004-05-26 NZ NZ543591A patent/NZ543591A/en unknown
- 2004-05-26 CA CA002634709A patent/CA2634709A1/en not_active Abandoned
- 2004-05-26 RS YUP-2005/0884A patent/RS20050884A/sr unknown
- 2004-05-26 CA CA002634766A patent/CA2634766A1/en not_active Abandoned
- 2004-05-26 US US10/558,208 patent/US20070098816A1/en not_active Abandoned
- 2004-05-26 WO PCT/JP2004/007562 patent/WO2004103369A1/en not_active Ceased
- 2004-05-26 CA CA002634765A patent/CA2634765A1/en not_active Abandoned
- 2004-05-26 CL CL200401278A patent/CL2004001278A1/es unknown
- 2004-05-26 CN CNA2008101007303A patent/CN101322707A/zh active Pending
- 2004-05-26 UA UAA200512454A patent/UA81499C2/xx unknown
- 2004-05-26 UY UY28330A patent/UY28330A1/es not_active Application Discontinuation
- 2004-05-26 AR ARP040101807A patent/AR045318A1/es not_active Application Discontinuation
- 2004-05-26 JP JP2006519178A patent/JP2006526031A/ja active Pending
- 2004-05-26 AU AU2004241873A patent/AU2004241873C1/en not_active Ceased
- 2004-05-26 KR KR1020057022615A patent/KR100938712B1/ko not_active Expired - Fee Related
- 2004-05-26 CN CNA2004800146332A patent/CN1794991A/zh active Pending
- 2004-05-26 CA CA002527191A patent/CA2527191A1/en not_active Abandoned
- 2004-05-26 TW TW093114934A patent/TW200505424A/zh unknown
-
2005
- 2005-11-14 IL IL171941A patent/IL171941A0/en unknown
- 2005-11-16 NO NO20055417A patent/NO20055417L/no not_active Application Discontinuation
- 2005-11-24 ZA ZA200509515A patent/ZA200509515B/en unknown
- 2005-11-25 CU CU20050237A patent/CU23490B7/es not_active IP Right Cessation
- 2005-12-22 CO CO05129159A patent/CO5660262A2/es unknown
- 2005-12-26 EC EC2005006253A patent/ECSP056253A/es unknown
-
2006
- 2006-01-02 CR CR8163A patent/CR8163A/es not_active Application Discontinuation